Abstract 569P
Background
Artificial intelligence (AI) algorithms have been developed to distinguish MMR-D from MMR-P (proficient) tumors, yet they lack biological interpretability. To address this shortcoming, we used validated AI algorithms to detect and quantify well described morphological features in colon cancers from whole slide images.
Methods
Digital images of stage III colon carcinomas from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147; Alliance) were utilized. Available MMR-D (n=191) and randomly selected MMR-P (n=188) cancers were analyzed. QuantCRC quantifies the amount of stroma and stromal subtypes (immature, mature, inflammatory) and tumor/stroma ratio in addition to grade, mucin, signet ring cells, budding/poorly differentiated clusters (TB/PDC) and tumor-infiltrating lymphocytes (TILs). We also distinguished TILs in epithelium vs stromal using another AI algorithm (Lunit SCOPE IO). Area under the curve (AUC), i.e., discrimination threshold, was measured for each feature to predict MMR status.
Results
Among AI-derived morphological features, significant differences were found by MMR status whereby dMMR cancers had lower immature stroma but higher inflammatory stroma, higher tumor grade, and increased mucin, signet ring cells, tumor size, TB/PDCs, and TILs (all Kruskal-Wallis p<0.05). Univariately, AUC (95% CI) values for prediction of MMR status above 0.6 were as follows: TILs 0.72 (0.67-0.77), immature stroma 0.67 (0.62-0.73); inflammatory stroma 0.67 (0.62-0.73); tumor grade 0.65 (0.60-0.71); signet ring cells 0.65 (0.60-0.71); mucin 0.64 (0.59-0.70). Given that TILs in the overall tumor was most discriminant, we then utilized a TIL-specific AI algorithm measuring TILs in epithelium and stroma and found that epithelial TILs had a significantly higher AUC [ 0.79 (0.74-0.84) compared to stromal TILs 0.58 (0.52-0.63) p<0.0001].
Conclusions
Among morphological tumor features quantified by AI, tumor immature desmoplastic stroma and TILs, particularly epithelial TIL densities, were best able to distinguish MMR-D from MMR-P tumors. These findings have implications for prognosis and subtype-based interventions and can guide spatial molecular interrogation.
Clinical trial identification
NCT00079274.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Supported by Institutional grant support. NIH U10CA180821, U10CA180882, U24CA196171, R01 CA210509 (to FAS). Study NCCTG N0147 received funds from Sanofi.
Disclosure
G. Park, Y. Lim: Financial Interests, Institutional, Member: Lunit. D. Yan, K. Shanmugam: Financial Interests, Institutional, Full or part-time Employment: Roche. C-Y. Ock: Financial Interests, Institutional, Member: Lunit. All other authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10